News

Social Media

 
 

Clinical Trial Programme

We are currently investigating the safety and efficacy of arimoclomol in Niemann-Pick type C (NPC). NPC is a rare, lysosomal storage disorder which affects around 1 in 150,000 newborns.


Are you a patient, caregiver or healthcare professional? Do you need more information about our approach? We want to hear from you!  Click here to contact us.

Contact Us